207_Combined course Presentations

 Phase II randomized trial , 49 patients enrolled  Stage IV NSCLC, 3 or fewer metastases  Primary Endpoint: PFS  First line therapy with 4+ platinum based doublet or 3+ months of EGFR or ALK inhibitors (if mutated)  Patients randomly assigned to:

Hypofx RT or SBRT 48% Surgery and RT 24% Chemo-beam 8% Hypofx RT and chemo-beam 12% Surgery 4%

A. Local therapy

20% received Chemo-radiation

Pemetrexed 67% Erlotinib 8% Afatinib 4% Bevacizumab 4% Observation 17%

B. Maintenance

Gomez DR. et al. Lancet Oncol 2016